Time to Throw in the Towel on Biosimilars
Peter Bach and Mark Trusheim of MIT Sloan School of Management underscore the drawbacks of Washington's preferred solution to introduce competition for biologics, the biosimilar model.
Originally published on 08/21/2019 in The Wall Street Journal
Authors previously published the proposal to abandon biosimilars, as biologic drugs hold natural monopolies in the market.
The biosimilar model's necessary testing requirements present additional limits on competition and divert eligible patients from novel, innovative clinical trials.